搜索优化
Rewards
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
过去 7 天
时间不限
过去 1 小时
过去 24 小时
过去 30 天
按相关度排序
按时间排序
来自MSN
1 天
GSK's Studies on Depemokimab for Nasal Polyps Meet Primary Goals (Revised)
GSK plc GSK announced positive data from the phase III ANCHOR-1 and ANCHOR-2 studies, which evaluated its pipeline candidate, ...
Zacks.com on MSN
1 天
GSK's Studies on Depemokimab for Nasal Polyps Meet Primary Goals
The phase III ANCHOR-1 and ANCHOR-2 studies evaluating GSK's depemokimab in adults with chronic rhinosinusitis with nasal ...
GlobalData on MSN
1 天
GSK’s depemokimab shows promise in Phase III trials for chronic rhinosinusitis
Both trials met their primary endpoints, indicating a significant improvement in patients treated with the drug.
FierceBiotech
2 天
GSK's depemokimab reduces polyps in phase 3 trials, adding weight to upcoming filing
GSK’s blockbuster hopes for depemokimab remain on track after the investigational long-acting asthma treatment has also been ...
pharmaphorum
2 天
GSK asthma hope depemokimab works in second indication
Depemokimab has already shown its potential as a therapy for severe asthma in two other phase 3 trials – SWIFT-1 and SWIFT-2 ...
1 天
GSK公布depemokimab三期临床试验结果喜人
GSK plc (LSE/NYSE: GSK) 宣布其用于治疗慢性鼻窦炎伴鼻息肉(CRSwNP)的药物depemokimab在ANCHOR三期临床试验中取得积极成果。根据新闻稿,该试验达到了主要终点,与安慰剂加标准治疗相比,在52周内显著减少了鼻息肉大小和鼻塞程度。 Depemokimab是一种超长效生物制剂,每半年给药一次,在靶向和抑制与鼻息肉生长和阻塞相关的炎症方面显示出了前景。 GSK高级副 ...
EuropaWire
2 天
GSK Reports Promising Phase III Findings for Depemokimab in Treating Chronic Rhinosinusitis ...
GSK plc has announced positive results from its Phase III ANCHOR trials for depemokimab, a biologic treatment for chronic ...
The Pharma Letter
2 天
GSK’s depemokimab scores well in CRSwNP trials
UK pharma major GSK today announced positive headline results from two Phase III clinical trials, ANCHOR-1 and ANCHOR-2, ...
腾讯网
2 天
葛兰素史克(GSK.US)实验性药物Depemokimab治疗鼻炎试验取得积极结果
智通财经APP获悉,葛兰素史克(GSK.US)用于治疗一种常见鼻炎的实验性药物在两项后期试验中显示出积极的结果,这促进了这家英国制药商的研发管道。据了解,Depemokimab有助于减少患有慢性鼻窦炎伴鼻息肉患者的鼻塞和息肉大小,葛兰素史克表示,这是 ...
2 天
GSK reports positive results from depemokimab trial
GSK has announced positive results from a phase III trial of its depemokimab treatment for chronic rhinosinusitis with nasal ...
2 天
GSK Says Depemokimab Achieves Positive Results in Phase 3 Trial
Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...
BioPharma Dive
2 天
GSK says antibody drug succeeds in testing for chronic nasal condition
The company has set high expectations for depemokimab, which it is also advancing in three other inflammatory diseases, including asthma.
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈